/ Do You Know?
Do you know?
Early diagnosis is the key of preventing metastasis of skin cancer.
According to multiple research and papers, visual or dermascopic examination is not good enough to confirm a skin cancer. Due to above reason, performing biopsy on suspicious region and asking dermatopathologist’s opinion is a common practice. However, this may result in; 1) a few more days waiting for pathology, 2) may result unnecessary biopsy for false positive skin cancer lesion, and 3) unnecessary scar.
If there exist a diagnosis method which can determine skin cancer risk with higher reliability, that is high sensitivity and high specificity, that will be a good solution to both physicians and patients.
Spectra-Scope® helps physicians make better clinical diagnosis by providing unrivaled accuracy, instant result, and prevent scar formation by reducing unnecessary biopsy, for all types of skin cancers. The combination of bio-chemical information of skin tissue as an outcome of laser induced plasma spectroscopy and a proprietary AI-based diagnostic algorithm allow for unrivaled clinical accuracy in both sensitivity and specificity.
Limitations of Current Skin Cancer Diagnosis
Science and modern medicine have made gigantic leaps in the prevention, diagnosis, and even treatment of skin cancer. Despite this, many people get the disease and leave it untreated for lengthy periods, resulting in degeneration of health and permanent disfigurement, sometimes even death.
Early accurate detection allows better treatment options and outcomes for skin cancer patients. For this reason, experts recommend a personal body check at least once a month. Upon discovery of anything irregular, the experts suggest consultation with dermatologists who usually check on the skin using skin surface microscopy or dermoscopy. Nevertheless, multiple studies say that those may not be entirely accurate, resulting in false-positive and unnecessary biopsy. Furthermore, the worst case is that a false-negative would cause detrimental results to the cancer patients’ life. The consequence of these leads to many disadvantages to cancer patients. For example, in the case of a false-positive, the cancer patients will spend unnecessary money for biopsy and will have unwanted scar left on the biopsy site. In the case of a false-negative, which is even worse, the patients will not have appropriate treatment; therefore, it decreases the survival rate of the cancer patients drastically. However, the use of Spectra-Scope® instead of the skin surface microscopy or dermoscopy, provides unrivaled accuracy and instant result, and reduces scar formations from unnecessary biopsy required in most cancer diagnoses.
Papageorgiou V, et al. The limitations of dermoscopy: false‐positive and false‐negative tumours. J Eur Acad Dermatol Venereol. 2018Jun;32(6):879-888
Carli P, et al. The problem of false-positive diagnosis in melanoma screening: the impact of dermoscopy. Melanoma Res. 2003 Apr;13(2):179-82
Elmore JG, et al. Pathologists' diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study. BMJ. 2017 Jun 28;357:j2813